Loading
Genotyping needle biopsies from 219 patients with advanced pancreatic cancer showed the KRAS G12D allele carried the shortest survival, six months against nine for other alleles and fourteen for G12R.
Multicentre prospective study: exon-2 KRAS status on EUS-guided fine-needle aspiration of the primary in locally advanced or metastatic pancreatic ductal carcinoma, with survival adjusted for age, stage, performance status, CA 19-9 and treatment. Of 219 patients, 147 had a codon-12 mutation (G12D 73, G12V 53, G12R 21) and 72 were wild-type. Survival did not differ between mutant and wild-type (8 versus 9 months), but G12D carried 6 months against 9 for the rest (hazard ratio 1.47), with G12V 9 and G12R 14 months; results held among 162 chemotherapy-treated patients (hazard ratio 1.66) and in multivariate analysis (1.44).
It is the allele-level prognosis behind reading the KRAS variant rather than 'KRAS mutant', and it shows the older EUS assay over-called wild-type (33%).
Shares KRAS G12D (and other non-G12C KRAS mutations), RASolute 302, KRAS mutation subtypes (G12C, G12D, G12V), KRAS & RAS inhibitors.
Shares RASolute 302, KRAS mutation subtypes (G12C, G12D, G12V), KRAS & RAS inhibitors, KRAS.
Shares KRAS G12D (and other non-G12C KRAS mutations), KRAS mutation subtypes (G12C, G12D, G12V), KRAS, Pancreatic ductal adenocarcinoma.
Shares KRAS & RAS inhibitors, Locally advanced unresectable pancreatic ductal adenocarcinoma, Metastatic pancreatic ductal adenocarcinoma.
Shares KRAS mutation subtypes (G12C, G12D, G12V), KRAS & RAS inhibitors, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares KRAS & RAS inhibitors, Locally advanced unresectable pancreatic ductal adenocarcinoma, Metastatic pancreatic ductal adenocarcinoma.
Shares KRAS mutation subtypes (G12C, G12D, G12V), KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma.
Shares KRAS mutation subtypes (G12C, G12D, G12V), KRAS & RAS inhibitors, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.